TI: Aspirin for the Primary Prevention of Cardiovascular Events in Women
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Effectiveness of Preemptive Antifibrinolysis with Tranexamic Acid
Lei et al. BMC Musculoskeletal Disorders (2020) 21:465 https://doi.org/10.1186/s12891-020-03488-8 STUDY PROTOCOL Open Access Effectiveness of preemptive antifibrinolysis with tranexamic acid in rheumatoid arthritis patients undergoing total knee arthroplasty: a study protocol for a randomized controlled trial Yiting Lei1†, Jiacheng Liu1†, Xi Liang1, Ning Hu1, Fuxing Pei2 and Wei Huang1* Abstract Background: Patients with rheumatoid arthritis (RA) who have undergone total knee arthroplasty are at increased risk of requiring a blood transfusion. This study is designed to compare the effects of preemptive antifibrinolysis of single-dose and repeat-dose tranexamic acid (TXA) in in RA patients undergoing total knee arthroplasty (TKA). Methods/design: The study will be a double-blind randomized controlled trial with two parallel groups of RA patients. Group A will be given 100 ml normal saline twice daily starting from 3 days before the operation, Group B will be given TXA 1.5 g twice daily starting from 3 days before the operation. All patients will be given TXA 1.5 g 30 min before the operation. The primary outcomes will be evaluated with total blood loss and hidden blood loss. Other outcome measurements such as, fibrinolysis parameters, inflammatory factors, visual analogue scale for post- operative pain, analgesia usage, coagulation parameters, transfusion, the length of stay (LOS), total hospitalization costs, the incidence of thromboembolic events and other complications will be recorded and compared. Recruitment is scheduled to begin on 1 August 2020, and the study will continue until 31 May 2021. Discussion: In current literature there is a lack of evidence with regard to the efficacy of TXA in RA patients. -
Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1. -
2019 National Library of Medicine Classification Schedules
National Library of Medicine Classification 2019 Schedule S-1 QS Human Anatomy Classify here general works on normal human anatomy. Works that treat men, women, or children separately are classed here. • Classify works on anatomy of a part of the body with the part. • Classify works on surgical anatomy in WO 101. • Classify works on artistic anatomy of human or animal in NC 760-783.8. • Classify works on anatomy of animals in QL or SF. QS 1-132 Anatomy QS 504-532 Histology QS 604-681 Embryology Anatomy Note that form numbers are also used under Histology (QS 504-539) and under Embryology (QS 604-681). QS 1 Organizations. Societies (General or not elsewhere classified) (Cutter from name of organization or society) (Table G) (Used for both monographs and serials) Includes membership lists issued serially or separately. Classify directories in QS 22. Classify annual reports, journals, etc., in W1. For academies and institutes, see QS 23-24. QS 4 General works Classify here works on regional anatomy. If written for the surgeon, classify in WO 101 Surgical anatomy. Classify material on comparative anatomy in QS 124. Collected works QS 5 By several authors QS 7 By individual authors QS 9 Addresses. Essays. Lectures QS 11 History (Table G) QS 11.1 General coverage (Not Table G) QS 13 Dictionaries. Encyclopedias QS 15 Classification. Terminology (Used for both monographs and serials) QS 16 Tables. Statistics. Surveys (Table G) (Used for both monographs and serials) QS 16.1 General coverage (Not Table G) (Used for both monographs and serials) QS 17 Atlases. -
AMEG Categorisation of Antibiotics
12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................ -
WSAVA List of Essential Medicines for Cats and Dogs
The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs ..................................................................................................................... -
Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity
molecules Review Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity Valery M. Dembitsky 1,2,*, Ekaterina Ermolenko 2, Nick Savidov 1, Tatyana A. Gloriozova 3 and Vladimir V. Poroikov 3 1 Centre for Applied Research, Innovation and Entrepreneurship, Lethbridge College, 3000 College Drive South, Lethbridge, AB T1K 1L6, Canada; [email protected] 2 A.V. Zhirmunsky National Scientific Center of Marine Biology, 17 Palchevsky Str., 690041 Vladivostok, Russia; [email protected] 3 Institute of Biomedical Chemistry, 10 Pogodinskaya Str., 119121 Moscow, Russia; [email protected] (T.A.G.); [email protected] (V.V.P.) * Correspondence: [email protected]; Tel.: +1-403-320-3202 (ext. 5463); Fax: +1-888-858-8517 Abstract: Polycyclic endoperoxides are rare natural metabolites found and isolated in plants, fungi, and marine invertebrates. The purpose of this review is a comparative analysis of the pharmacological potential of these natural products. According to PASS (Prediction of Activity Spectra for Substances) estimates, they are more likely to exhibit antiprotozoal and antitumor properties. Some of them are now widely used in clinical medicine. All polycyclic endoperoxides presented in this article demonstrate antiprotozoal activity and can be divided into three groups. The third group includes endoperoxides, which show weak antiprotozoal activity with a reliability of up to 70%, and this group includes only 1.1% of metabolites. The second group includes the largest number of endoperoxides, Citation: Dembitsky, V.M.; which are 65% and show average antiprotozoal activity with a confidence level of 70 to 90%. Lastly, Ermolenko, E.; Savidov, N.; the third group includes endoperoxides, which are 33.9% and show strong antiprotozoal activity with Gloriozova, T.A.; Poroikov, V.V. -
Tuberculosis Medicines Technology and Market Landscape
2014 Tuberculosis Medicines Technology and Market Landscape OCTOBER 2014 2014 Tuberculosis Medicines Technology and Market Landscape UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 [email protected] www.unitaid.org UNITAID is hosted and administered by the World Health Organization © 2014 World Health Organization (acting as the host organization for the Secretariat of UNITAID) The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind either expressed or implied. The responsibility and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Overall coordination of this report was undertaken by Janet Ginnard. Components of this report were prepared by Patrick Aylward, Philippa Crompton, Colleen Daniels, Janet Ginnard, Erica Lessem and Megan Paterson with support from UNITAID. All reasonable precautions have been taken by the authors to verify the information contained in this publication. -
Type IA Topoisomerases As Targets for Infectious Disease Treatments
microorganisms Review Type IA Topoisomerases as Targets for Infectious Disease Treatments Ahmed Seddek 1,2 , Thirunavukkarasu Annamalai 1 and Yuk-Ching Tse-Dinh 1,2,* 1 Department of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA; asedd001@fiu.edu (A.S.); athiruna@fiu.edu (T.A.) 2 Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA * Correspondence: ytsedinh@fiu.edu; Tel.: +1-305-348-4956 Abstract: Infectious diseases are one of the main causes of death all over the world, with antimi- crobial resistance presenting a great challenge. New antibiotics need to be developed to provide therapeutic treatment options, requiring novel drug targets to be identified and pursued. DNA topoi- somerases control the topology of DNA via DNA cleavage–rejoining coupled to DNA strand passage. The change in DNA topological features must be controlled in vital processes including DNA repli- cation, transcription, and DNA repair. Type IIA topoisomerases are well established targets for antibiotics. In this review, type IA topoisomerases in bacteria are discussed as potential targets for new antibiotics. In certain bacterial pathogens, topoisomerase I is the only type IA topoisomerase present, which makes it a valuable antibiotic target. This review will summarize recent attempts that have been made to identify inhibitors of bacterial topoisomerase I as potential leads for antibiotics and use of these inhibitors as molecular probes in cellular studies. Crystal structures of inhibitor–enzyme complexes and more in-depth knowledge of their mechanisms of actions will help to establish the structure–activity relationship of potential drug leads and develop potent and selective therapeutics that can aid in combating the drug resistant bacterial infections that threaten public health. -
Statistical Analysis Plan – Part 1
NCT03251482 Janssen Research & Development Statistical Analysis Plan – Part 1 A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery Protocol 64179375THR2001; Phase 2 JNJ-64179375 Status: Approved Date: 18 October 2017 Prepared by: Janssen Research & Development, LLC Document No.: EDMS-ERI-148215770 Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential. 1 Approved, Date: 18 October 2017 JNJ-64179375 NCT03251482 Statistical Analysis Plan - Part 1 64179375THR2001 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................... 2 LIST OF IN-TEXT TABLES AND FIGURES ............................................................................................... -
Current Status of Antifibrinolytics in Cardiopulmonary Bypass and Elective Deep Hypothermic Circulatory Arrest Jeffrey A
Anesthesiology Clin N Am 21 (2003) 527–551 Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest Jeffrey A. Green, MD*, Bruce D. Spiess, MD Department of Anesthesiology, Virginia Commonwealth University, Medical College of Virginia Campus, 1200 East Broad Street, PO Box 980695, Richmond, VA 23209 USA Bleeding after cardiopulmonary bypass Cardiopulmonary bypass (CPB) alters the hemostatic balance and predisposes cardiac surgery patients to an increased risk of microvascular bleeding. Bleeding and the need for transfusion are among the most common complications of cardiac surgery. In fact, until recently, blood transfusions seemed to be required for about 50% of all cardiac surgery patients [1]. Currently, CPB accounts for 10% to 20% of the transfusions performed in the United States [2,3]. Transfusion, however, exposes patients to added risks such as infectious disease transmission [4], transfusion reactions [5], graft-versus-host disease [6], transfusion-induced lung injury [7], and decreased resistance to postoperative infection [8,9]. Transfusion increases the risk of infection by 35% to 300% and increases the risk of pneumonia in coronary artery bypass (CABG) patients by 5% per unit transfused [10]. The primary purported benefit of transfusion, increased oxygen carrying capacity, has not been definitively proven. Excessive postoperative bleeding may necessitate surgical reexploration, increasing morbidity, and mortality. Postoperatively, the risk of excessive bleeding is 11% [11], and 5% to 7% of patients lose more than 2 L of blood in the first 24 hours after CPB [12]. Reexploration for hemorrhage is required in 3.6% to 4.2% of patients [13], and mortality rates range from 10% to 22% [14]. -
Proposal for Inclusion of Tranexamic Acid in the Who List of Essential Medicines
PROPOSAL FOR INCLUSION OF TRANEXAMIC ACID IN THE WHO LIST OF ESSENTIAL MEDICINES General items 1. Summary statement of the proposal for inclusion, change or deletion. Tranexamic acid (TXA) is included in the EML as a medicine affecting the blood/medicines affecting coagulation. This proposal is to request the inclusion of TXA in the World Health Organization (WHO) Model Lists of Essential Medicines (EML) for treatment of postpartum haemorrhage (PPH) as an additional indication in the section covering maternal health medicines. TXA should be administered to the woman, as part of the standard PPH treatment package, as soon as possible after the onset of bleeding and within 3 hours of birth.1 TXA should be administered at a fixed dose of 1 g in 10 ml (100 mg/ml) IV at 1 ml per minute, with a second dose of 1 g IV if bleeding continues after 30 minutes. TXA is a competitive inhibitor of plasminogen activation and reduces bleeding by inhibiting the breakdown of fibrinogen and fibrin clots. In 2017, a large randomized controlled trial showed that early use of IV TXA reduces death due to bleeding in women with PPH, regardless of the cause, and with no adverse maternal effects.2 Based on this evidence, on the Cochrane systematic review on the efficacy of TXA for PPH, and on an individual meta-analysis of 40,138 bleeding patients, WHO updated its PPH treatment recommendations to include use of TXA for treatment of PPH in 2017.1,3 2. Relevant WHO technical department and focal point Department of Reproductive Health and Research (RHR). -
Urticaria and Angioedema
Urticaria and Angioedema This guideline, developed by Robbie Pesek, MD and Allison Burbank, MD, in collaboration with the ANGELS team, on July 23, 2013, is a significantly revised version of the guideline originally developed by Jeremy Bufford, MD. Last reviewed by Robbie Pesek, MD September 14, 2016. Key Points Urticaria and angioedema are common problems and can be caused by both allergic and non- allergic mechanisms. Prompt diagnosis of hereditary angioedema (HAE) is important to prevent morbidity and mortality. Several new therapeutic options are now available. Patients with urticaria and/or angioedema should be referred to an allergist/immunologist for symptoms that are difficult to control, suspicion of HAE, or to rule out suspected allergic triggers. Definition, Assessment, and Diagnosis Definitions Urticaria is a superficial skin reaction consisting of erythematous, raised, blanching, well- circumscribed or confluent pruritic, edematous wheals, often with reflex erythema.1-3 Urticarial lesions are typically pruritic, and wax/wane with resolution of individual lesions within 24 hours. Angioedema is localized swelling of deep dermal, subcutaneous, or submucosal tissue resulting from similar vascular changes that contribute to urticaria.1,2 Angioedema may be pruritic and/or painful and can last for 2-3 days depending on etiology.3 1 Urticaria alone occurs in 50% of patients and is associated with angioedema in 40% of patients. Isolated angioedema occurs in 10% of patients.1,2 Hereditary angioedema (HAE) is a disorder involving defects in complement, coagulation, kinin, and fibrinolytic pathways that results in recurrent episodes of angioedema without urticaria, usually affecting the skin, upper airway, and gastrointestinal tract.4 In children, acute urticaria is more common than chronic forms.